In designing a Src inhibitor, Ariad Pharmaceuticals Inc. has overcome hurdles that have tripped up the big pharmaceutical companies and provided a new mechanism for treating osteoporosis.

ARIA (Cambridge, Mass.) last week published, in the Proceedings of the National Academy of Sciences, that it had designed a low nanomolar inhibitor of the Src (pronounced sarc) homology 2 domain (SH2) for preventing osteoclast-mediated bone resorption (see B10).